acos brainstorming webinar presentation1.ppt brainstorming webi… · microsoft powerpoint - acos...
TRANSCRIPT
WelcomeACoS Brainstorming Webinar
Dr. Youjie Huang◦ DOH – CER PI
Dr. Jill MacKinnonFCDS Project Director◦ FCDS – Project Director
Dr. Monique Hernandez◦ FCDS – CER Project ManagerFCDS CER Project Manager
Mike Thiry◦ FCDS – Manager for Data Acquisition
Steve Peace, CTR◦ FCDS – Manager for Quality Control and Education
2
Enhancing Cancer Registry Data for C i Eff i R hComparative Effectiveness Research
Cancer Surveillance Branch Division of Cancer Prevention and s o o Ca ce e e t o a d
Control Centers for Disease Control andCenters for Disease Control and
Prevention
Funding Opportunity for the fNational Program of Cancer Registries
3
Activities will include additional data collection, training, methodological d l t d i f l t idevelopment, and expansion of electronic reporting with the goal of supporting Comparative Effectiveness Research and toComparative Effectiveness Research and to develop sustainable methods to enhance cancer registry data for public health and g y presearch.
4
Department of Health application◦ 1 of 10 States funded
Innovative designExtensive utilization of electronic data streams◦ Extensive utilization of electronic data streams
5
Cases◦ Diagnosed in 2011 only
Primary sitesBreast Colorectal and CML◦ Breast, Colorectal and CML
Regions◦ Miami-Dade, Broward, Palm Beach, Orange andMiami Dade, Broward, Palm Beach, Orange and
Hillsborough Counties Project Period:◦ December 2010 – September 2013
6
Are colorectal cancer patients tested for KRAS and are the results used pappropriately to determine treatment? What impact does KRAS testing have on 2-3 year survival among colorectal cancer patients?
Are rectal cancer patients receiving radiotherapy and what is the timing f di th ? A di iti t i th i tof radiotherapy? Are disparities apparent in the appropriate neo-
adjuvant use of radiotherapy among these patients?
Are chronic myeloid leukemia (CML) patients being tested for the BCR-ABL2 gene and receiving appropriate treatment according to thoseABL2 gene and receiving appropriate treatment according to those results?
Are women with breast cancer being tested appropriately for HER2, progesterone receptor (PR2) and estrogen receptor (ER) status andprogesterone receptor (PR2), and estrogen receptor (ER) status and treated appropriately?
7
HospitalsPh i i ffi
AHCA discharge summaries Physician offices
Pathology laboratories RT/AS facilities
summaries Vital Statistics National Death Index
RT/AS facilities Census Medical claims Medicare Medicare Medicaid
Active Data Collection Passive Data CollectionC C
8
Table 1 - Required Data for All Cancers Diagnosed in 2011Data Items Regional or
StatewideData Source
StatewideAll NPCR required standard data items as described in NAACCR Vol. 2 - for 2011 diagnoses, including complete treatment information and associated date fields
Statewide Data Reporters
All Collaborative Stage Version 2 (CSv2) data items necessary to calculate the American Joint Commission on Cancer TNM Stage, 6th and 7th Edition. AJCC TNM stage
Statewide Data Reporters
JAK2 for hematopoietic cancers Statewide Data ReportersCo-Morbid conditions Statewide FCDSHeight Statewide* Data ReportersWeight Statewide* Data ReportersSmoking status Statewide* Data Reportersg pVital statusDate of Last Contact [NAACCR Item 1750], Vital Status [NAACCR Item 1760], Follow-Up Source Central [NAACCR Item 1791], Cause of Death [NAACCR Item 1910],
Statewide FCDS
], [ ],ICD-revision number [NAACCR Item 1920]
Census tract level SES and area health professional availability; area level health insurance
Statewide FCDS
Urban / Rural location Statewide FCDSUrban / Rural location Statewide FCDSMDE/NBCCEDP linkage variable Statewide FCDS*New FCDS 2011 required data item
9
Table 2 - Additional Required Data to Evaluate CER Questions Related to Breast Cancers, Colorectal Cancers, and Chronic Myeloid LeukemiaBreast Cancers, Colorectal Cancers, and Chronic Myeloid LeukemiaData Items Regional or Statewide Data Source
Treatment regimes - specific chemotherapeutic agents; number of courses
CER Counties CER Data Reporters
and dose administered; treatment dates; biological response modifiers; hormone therapy and drugs such as Tamoxifen used during first course of treatment; use of neo-adjuvant therapy
Reason for Alteration/Interruption of Treatment- if planned dose is not received
CER Counties CER Data Reporters
Prognostic biomarkers; biomarkers affecting treatment decisions; and staging related biomarkers - including the following; KRAS; HER2 ER and PR
StatewideException (CER Counties only): BCR-ABL2 Reason: no SSF
CER Data Reporters
following; KRAS; HER2, ER and PR status; BCR-ABL2; micro-satellite instability;
ABL2 Reason: no SSF exists
Clinical stage (pre-adjuvant therapy) for CER Counties CER Data Reportersg (p j py)invasive breast; and rectum only
CER Data Reporters
10
Planning since June 2010 Innovative ideas for data gathering◦ Combination of electronic data streams hoping to
minimize manual data collectionminimize manual data collection Developed tools◦ Florida alone◦ All CER states collectively
11
Ultimate goal is to form a task force to helpUltimate goal is to form a task force to help advise us all along the way
As much or a little as desired
More information about this after Steve fills i h d d ilyou in on the data details
Steve take it awaySteve take it away
13
Monique Hernandez◦ CER Project Manager◦ [email protected]◦ (305) 243-9673◦ (305) 243 9673
14